{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:24:20Z","timestamp":1793910260899,"version":"4.8.0"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"DOI":"10.1038\/s41577-026-01345-8","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:09:11Z","timestamp":1788361751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Interleukin-33 and its receptor: multifaceted roles and emerging therapeutic potential"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9839-7119","authenticated-orcid":false,"given":"Sebastian","family":"Serve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6382-7281","authenticated-orcid":false,"given":"Max","family":"L\u00f6hning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"1345_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003331","volume":"3","author":"C Moussion","year":"2008","unstructured":"Moussion, C., Ortega, N. & Girard, J.-P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel \u2018alarmin\u2019? PLoS ONE 3, e3331 (2008). This study establishes IL-33 as a constitutively expressed alarmin in endothelial and epithelial cells.","journal-title":"PLoS ONE"},{"key":"1345_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.coi.2014.09.004","volume":"31","author":"C Cayrol","year":"2014","unstructured":"Cayrol, C. & Girard, J. P. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr. Opin. Immunol. 31, 31\u201337 (2014).","journal-title":"Curr. Opin. Immunol."},{"key":"1345_CR3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nri.2016.95","volume":"16","author":"FY Liew","year":"2016","unstructured":"Liew, F. Y., Girard, J.-P. & Turnquist, H. R. Interleukin-33 in health and disease. Nat. Rev. Immunol. 16, 676\u2013689 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"1345_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","volume":"281","author":"CA Dinarello","year":"2018","unstructured":"Dinarello, C. A. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol. Rev. 281, 8\u201327 (2018).","journal-title":"Immunol. Rev."},{"key":"1345_CR5","doi-asserted-by":"publisher","first-page":"18660","DOI":"10.1073\/pnas.0705939104","volume":"104","author":"S Ali","year":"2007","unstructured":"Ali, S. et al. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc. Natl Acad. Sci. USA 104, 18660\u201318665 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1345_CR6","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.str.2009.08.009","volume":"17","author":"A Lingel","year":"2009","unstructured":"Lingel, A. et al. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors-insight into heterotrimeric IL-1 signaling complexes. Structure 17, 1398\u20131410 (2009).","journal-title":"Structure"},{"key":"1345_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","volume":"23","author":"J Schmitz","year":"2005","unstructured":"Schmitz, J. et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479\u2013490 (2005). This study identifies IL-33 as a ligand for ST2, defining its ability to induce ST2-dependent immune responses.","journal-title":"Immunity"},{"key":"1345_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/0014-5793(89)81679-5","volume":"258","author":"S Tominaga","year":"1989","unstructured":"Tominaga, S. A putative protein of a growth specific cDNA from BALB\/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 258, 301\u2013304 (1989).","journal-title":"FEBS Lett."},{"key":"1345_CR9","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1073\/pnas.86.15.5708","volume":"86","author":"R Klemenz","year":"1989","unstructured":"Klemenz, R., Hoffmann, S. & Werenskiold, A. K. Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc. Natl Acad. Sci. USA 86, 5708\u20135712 (1989).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1345_CR10","doi-asserted-by":"publisher","first-page":"6930","DOI":"10.1073\/pnas.95.12.6930","volume":"95","author":"M L\u00f6hning","year":"1998","unstructured":"L\u00f6hning, M. et al. T1\/ST2 is preferentially expressed on murine TH2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for TH2 effector function. Proc. Natl Acad. Sci. USA\u00a095, 6930\u20136935 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1345_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1074\/jbc.271.1.124","volume":"271","author":"T G\u00e4chter","year":"1996","unstructured":"G\u00e4chter, T., Werenskiold, A. K. & Klemenz, R. Transcription of the interleukin-1 receptor-related T1 gene is initiated at different promoters in mast cells and fibroblasts. J. Biol. Chem. 271, 124\u2013129 (1996).","journal-title":"J. Biol. Chem."},{"key":"1345_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1084\/jem.187.5.787","volume":"187","author":"D Xu","year":"1998","unstructured":"Xu, D. et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J. Exp. Med. 187, 787\u2013794 (1998).","journal-title":"J. Exp. Med."},{"key":"1345_CR13","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.4049\/jimmunol.1101977","volume":"188","author":"M Pichery","year":"2012","unstructured":"Pichery, M. et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J. Immunol. 188, 3488\u20133495 (2012).","journal-title":"J. Immunol."},{"key":"1345_CR14","doi-asserted-by":"publisher","first-page":"155891","DOI":"10.1016\/j.cyto.2022.155891","volume":"156","author":"C Cayrol","year":"2022","unstructured":"Cayrol, C. & Girard, J. P. Interleukin-33 (IL-33): a critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine. Cytokine 156, 155891 (2022).","journal-title":"Cytokine"},{"key":"1345_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.neuron.2015.01.013","volume":"85","author":"SP Gadani","year":"2015","unstructured":"Gadani, S. P., Walsh, J. T., Smirnov, I., Zheng, J. & Kipnis, J. The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury. Neuron 85, 703\u2013709 (2015).","journal-title":"Neuron"},{"key":"1345_CR16","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1126\/science.aal3589","volume":"359","author":"ID Vainchtein","year":"2018","unstructured":"Vainchtein, I. D. et al. Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development. Science 359, 1269\u20131273 (2018).","journal-title":"Science"},{"key":"1345_CR17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20241188","volume":"222","author":"N Fonta","year":"2025","unstructured":"Fonta, N. et al. Oligodendrocyte-derived IL-33 regulates self-reactive CD8+ T cells in CNS autoimmunity. J. Exp. Med. 222, e20241188 (2025).","journal-title":"J. Exp. Med."},{"key":"1345_CR18","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.3389\/fimmu.2018.02596","volume":"9","author":"K Fairlie-Clarke","year":"2018","unstructured":"Fairlie-Clarke, K. et al. Expression and function of IL-33\/ST2 axis in the central nervous system under normal and diseased conditions. Front. Immunol. 9, 2596 (2018).","journal-title":"Front. Immunol."},{"key":"1345_CR19","doi-asserted-by":"publisher","first-page":"eaaw3658","DOI":"10.1126\/sciimmunol.aaw3658","volume":"4","author":"RG Spallanzani","year":"2019","unstructured":"Spallanzani, R. G. et al. Distinct immunocyte-promoting and adipocyte-generating stromal components coordinate adipose tissue immune and metabolic tenors. Sci. Immunol. 4, eaaw3658 (2019).","journal-title":"Sci. Immunol."},{"key":"1345_CR20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/eji.201948413","volume":"51","author":"P Aparicio-Domingo","year":"2021","unstructured":"Aparicio-Domingo, P. et al. Fibroblast-derived IL-33 is dispensable for lymph node homeostasis but critical for CD8 T-cell responses to acute and chronic viral infection. Eur. J. Immunol. 51, 76\u201390 (2021). This study demonstrates that fibroblastic reticular cells in secondary lymphoid organs are a major source of IL-33 driving antiviral T cell responses.","journal-title":"Eur. J. Immunol."},{"key":"1345_CR21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.immuni.2019.02.002","volume":"50","author":"MW Dahlgren","year":"2019","unstructured":"Dahlgren, M. W. et al. Adventitial stromal cells define group 2 innate lymphoid cell tissue niches. Immunity 50, 707\u2013722 (2019).","journal-title":"Immunity"},{"key":"1345_CR22","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41590-018-0094-2","volume":"19","author":"AC Kohlgruber","year":"2018","unstructured":"Kohlgruber, A. C. et al. \u03b3\u03b4 T cells producing interleukin-17A regulate adipose regulatory T cell homeostasis and thermogenesis. Nat. Immunol. 19, 464\u2013474 (2018).","journal-title":"Nat. Immunol."},{"key":"1345_CR23","doi-asserted-by":"publisher","first-page":"eaax0416","DOI":"10.1126\/sciimmunol.aax0416","volume":"4","author":"T Mahlakoiv","year":"2019","unstructured":"Mahlakoiv, T. et al. Stromal cells maintain immune cell homeostasis in adipose tissue via production of interleukin-33. Sci. Immunol. 4, eaax0416 (2019).","journal-title":"Sci. Immunol."},{"key":"1345_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05485-x","volume":"9","author":"J Travers","year":"2018","unstructured":"Travers, J. et al. Chromatin regulates IL-33 release and extracellular cytokine activity. Nat. Commun. 9, 3244 (2018).","journal-title":"Nat. Commun."},{"key":"1345_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jaut.2014.02.012","volume":"55","author":"J Bessa","year":"2014","unstructured":"Bessa, J. et al. Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation. J. Autoimmun. 55, 33\u201341 (2014).","journal-title":"J. Autoimmun."},{"key":"1345_CR26","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/embor.2008.145","volume":"9","author":"L Roussel","year":"2008","unstructured":"Roussel, L., Erard, M., Cayrol, C. & Girard, J. P. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A\u2013H2B acidic pocket. EMBO Rep. 9, 1006\u20131012 (2008).","journal-title":"EMBO Rep."},{"key":"1345_CR27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nature00858","volume":"418","author":"P Scaffidi","year":"2002","unstructured":"Scaffidi, P., Misteli, T. & Bianchi, M. E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191\u2013195 (2002).","journal-title":"Nature"},{"key":"1345_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21589-2","volume":"8","author":"IC Scott","year":"2018","unstructured":"Scott, I. C. et al. Interleukin-33 is activated by allergen- and necrosis-associated proteolytic activities to regulate its alarmin activity during epithelial damage. Sci. Rep. 8, 3363 (2018).","journal-title":"Sci. Rep."},{"key":"1345_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.bbrc.2009.07.018","volume":"387","author":"M Hayakawa","year":"2009","unstructured":"Hayakawa, M. et al. Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. Biochem. Biophys. Res. Commun. 387, 218\u2013222 (2009).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1345_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.immuni.2009.05.007","volume":"31","author":"AU L\u00fcthi","year":"2009","unstructured":"L\u00fcthi, A. U. et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31, 84\u201398 (2009).","journal-title":"Immunity"},{"key":"1345_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9327","volume":"6","author":"ES Cohen","year":"2015","unstructured":"Cohen, E. S. et al. Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat. Commun. 6, 8327 (2015).","journal-title":"Nat. Commun."},{"key":"1345_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-36642-y","volume":"13","author":"E England","year":"2023","unstructured":"England, E. et al. Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE\/EGFR to reduce inflammation and epithelial dysfunction. Sci. Rep. 13, 9825 (2023).","journal-title":"Sci. Rep."},{"key":"1345_CR33","doi-asserted-by":"publisher","first-page":"2202210","DOI":"10.1183\/13993003.02210-2022","volume":"62","author":"S Strickson","year":"2023","unstructured":"Strickson, S. et al. Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE\/EGFR signalling complex. Eur. Respir. J. 62, 2202210 (2023). This study suggests ST2-independent signalling of oxidized IL-33 via RAGE\u2013EGFR complexes in epithelial cells.","journal-title":"Eur. Respir. J."},{"key":"1345_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0014-5793(93)81333-U","volume":"318","author":"K Yanagisawa","year":"1993","unstructured":"Yanagisawa, K., Takagi, T., Tsukamoto, T., Tetsuka, T. & Tominaga, S. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett. 318, 83\u201387 (1993).","journal-title":"FEBS Lett."},{"key":"1345_CR35","doi-asserted-by":"publisher","first-page":"26369","DOI":"10.1074\/jbc.M704916200","volume":"282","author":"H Hayakawa","year":"2007","unstructured":"Hayakawa, H., Hayakawa, M., Kume, A. & Tominaga, S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J. Biol. Chem. 282, 26369\u201326380 (2007).","journal-title":"J. Biol. Chem."},{"key":"1345_CR36","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cyto.2008.03.008","volume":"42","author":"G Palmer","year":"2008","unstructured":"Palmer, G. et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 42, 358\u2013364 (2008).","journal-title":"Cytokine"},{"key":"1345_CR37","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.4049\/jimmunol.0802729","volume":"182","author":"K Bulek","year":"2009","unstructured":"Bulek, K. et al. The essential role of single Ig IL-1 receptor-related molecule\/Toll IL-1R8 in regulation of TH2 immune response. J. Immunol. 182, 2601\u20132609 (2009).","journal-title":"J. Immunol."},{"key":"1345_CR38","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3389\/fimmu.2012.00322","volume":"3","author":"F Riva","year":"2012","unstructured":"Riva, F. et al. TIR8\/SIGIRR is an Interleukin-1 receptor\/Toll-like receptor family member with regulatory functions in inflammation and immunity. Front. Immunol. 3, 322 (2012).","journal-title":"Front. Immunol."},{"key":"1345_CR39","doi-asserted-by":"publisher","first-page":"218","DOI":"10.15252\/embj.201489456","volume":"34","author":"DA Holmes","year":"2015","unstructured":"Holmes, D. A., Yeh, J. H., Yan, D., Xu, M. & Chan, A. C. Dusp5 negatively regulates IL-33-mediated eosinophil survival and function. EMBO J. 34, 218\u2013235 (2015).","journal-title":"EMBO J."},{"key":"1345_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06468-8","volume":"9","author":"T Yamamoto","year":"2018","unstructured":"Yamamoto, T. et al. DUSP10 constrains innate IL-33-mediated cytokine production in ST2hi memory-type pathogenic TH2 cells. Nat. Commun. 9, 4231 (2018).","journal-title":"Nat. Commun."},{"key":"1345_CR41","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.immuni.2024.03.017","volume":"57","author":"L Yang","year":"2024","unstructured":"Yang, L. et al. Intraepithelial mast cells drive gasdermin C-mediated type 2 immunity. Immunity 57, 1056\u20131070 (2024). This study shows IL-33 release via a gasdermin C-mediated pore-forming pathway in epithelial cells.","journal-title":"Immunity"},{"key":"1345_CR42","doi-asserted-by":"publisher","first-page":"eabl7209","DOI":"10.1126\/sciimmunol.abl7209","volume":"7","author":"R Yamagishi","year":"2022","unstructured":"Yamagishi, R. et al. Gasdermin D-mediated release of IL-33 from senescent hepatic stellate cells promotes obesity-associated hepatocellular carcinoma. Sci. Immunol. 7, eabl7209 (2022).","journal-title":"Sci. Immunol."},{"key":"1345_CR43","doi-asserted-by":"publisher","first-page":"6941","DOI":"10.1074\/jbc.M111.298703","volume":"287","author":"R Kakkar","year":"2012","unstructured":"Kakkar, R., Hei, H., Dobner, S. & Lee, R. T. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J. Biol. Chem. 287, 6941\u20136948 (2012).","journal-title":"J. Biol. Chem."},{"key":"1345_CR44","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41590-023-01697-6","volume":"25","author":"TM Brunner","year":"2024","unstructured":"Brunner, T. M. et al. A type 1 immunity-restricted promoter of the IL-33 receptor gene directs antiviral T-cell responses. Nat. Immunol. 25, 256\u2013267 (2024). This study re-writes the genomic landscape of the IL-33 receptor ST2 and shows that its expression is controlled by at least 3 distinct promoters, one of them selectively active in type 1 immune cells and another one in type 2 immune cells, thus providing a mechanistic framework for the context-dependent effects of IL-33.","journal-title":"Nat. Immunol."},{"key":"1345_CR45","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1002\/eji.201142274","volume":"42","author":"BP Lipsky","year":"2012","unstructured":"Lipsky, B. P., Toy, D. Y., Swart, D. A., Smithgall, M. D. & Smith, D. Deletion of the ST2 proximal promoter disrupts fibroblast-specific expression but does not reduce the amount of soluble ST2 in circulation. Eur. J. Immunol. 42, 1863\u20131869 (2012).","journal-title":"Eur. J. Immunol."},{"key":"1345_CR46","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/j.1460-2075.1994.tb06367.x","volume":"13","author":"G Bergers","year":"1994","unstructured":"Bergers, G., Reikerstorfer, A., Braselmann, S., Graninger, P. & Busslinger, M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J. 13, 1176\u20131188 (1994).","journal-title":"EMBO J."},{"key":"1345_CR47","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.1073\/pnas.88.12.5114","volume":"88","author":"G Superti-Furga","year":"1991","unstructured":"Superti-Furga, G., Bergers, G., Picard, D. & Busslinger, M. Hormone-dependent transcriptional regulation and cellular transformation by Fos-steroid receptor fusion proteins. Proc. Natl Acad. Sci. USA 88, 5114\u20135118 (1991).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1345_CR48","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1073\/pnas.91.9.3896","volume":"91","author":"T Tr\u00fcb","year":"1994","unstructured":"Tr\u00fcb, T., Kalousek, M. B., Fr\u00f6hli, E. & Klemenz, R. Growth factor-mediated induction of the delayed early gene T1 depends on a 12-O-tetradecanoylphorbol 13-acetate-responsive element located 3.6 kb upstream of the transcription initiation site. Proc. Natl Acad. Sci. USA 91, 3896\u20133900 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1345_CR49","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/ni.3085","volume":"16","author":"A Vasanthakumar","year":"2015","unstructured":"Vasanthakumar, A. et al. The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat. Immunol. 16, 276\u2013285 (2015).","journal-title":"Nat. Immunol."},{"key":"1345_CR50","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1161\/01.CIR.0000038705.69871.D9","volume":"106","author":"EO Weinberg","year":"2002","unstructured":"Weinberg, E. O. et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106, 2961\u20132966 (2002).","journal-title":"Circulation"},{"key":"1345_CR51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/02724570050031194","volume":"19","author":"K Kuroiwa","year":"2000","unstructured":"Kuroiwa, K. et al. Construction of ELISA system to quantify human ST2 protein in sera of patients. Hybridoma 19, 151\u2013159 (2000).","journal-title":"Hybridoma"},{"key":"1345_CR52","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.164.2.2008120","volume":"164","author":"K Oshikawa","year":"2001","unstructured":"Oshikawa, K. et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am. J. Respir. Crit. Care Med. 164, 277\u2013281 (2001).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1345_CR53","first-page":"401","volume":"5","author":"H Hayakawa","year":"2016","unstructured":"Hayakawa, H., Hayakawa, M. & Tominaga, S. I. Soluble ST2 suppresses the effect of interleukin-33 on lung type 2 innate lymphoid cells. Biochem. Biophys. Rep. 5, 401\u2013407 (2016).","journal-title":"Biochem. Biophys. Rep."},{"key":"1345_CR54","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1126\/science.1215418","volume":"335","author":"WV Bonilla","year":"2012","unstructured":"Bonilla, W. V. et al. The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses. Science 335, 984\u2013989 (2012). This study reveals the key role of IL-33 in promoting CD8\u207a T cell activation and expansion in response to viral infection.","journal-title":"Science"},{"key":"1345_CR55","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1111\/all.15401","volume":"77","author":"M Watanabe","year":"2022","unstructured":"Watanabe, M. et al. Soluble ST2 enhances IL-33-induced neutrophilic and pro-type 2 inflammation in the lungs. Allergy 77, 3137\u20133141 (2022).","journal-title":"Allergy"},{"key":"1345_CR56","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.immuni.2009.12.004","volume":"32","author":"AN Hegazy","year":"2010","unstructured":"Hegazy, A. N. et al. Interferons direct Th2 cell reprogramming to generate a stable GATA-3+T-bet+ cell subset with combined Th2 and Th1 cell functions. Immunity 32, 116\u2013128 (2010).","journal-title":"Immunity"},{"key":"1345_CR57","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1073\/pnas.1418549112","volume":"112","author":"C Baumann","year":"2015","unstructured":"Baumann, C. et al. T-bet- and STAT4-dependent IL-33 receptor expression directly promotes antiviral TH1 cell responses. Proc. Natl Acad. Sci. USA 112, 4056\u20134061 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1345_CR58","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.3389\/fimmu.2019.01833","volume":"10","author":"C Baumann","year":"2019","unstructured":"Baumann, C. et al. Memory CD8+ T cell protection from viral reinfection depends on interleukin-33 alarmin signals. Front. Immunol. 10, 1833 (2019).","journal-title":"Front. Immunol."},{"key":"1345_CR59","doi-asserted-by":"publisher","first-page":"eadl0370","DOI":"10.1126\/science.adl0370","volume":"384","author":"ACH Szeto","year":"2024","unstructured":"Szeto, A. C. H. et al. Mef2d potentiates type-2 immune responses and allergic lung inflammation. Science 384, eadl0370 (2024). This study identifies the transcription factor MEF2D as a potentiator of IL-33-driven type 2 immune responses.","journal-title":"Science"},{"key":"1345_CR60","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.it.2016.03.007","volume":"37","author":"M Peine","year":"2016","unstructured":"Peine, M., Marek, R. M. & L\u00f6hning, M. IL-33 in T cell differentiation, function, and immune homeostasis. Trends Immunol. 37, 321\u2013333 (2016).","journal-title":"Trends Immunol."},{"key":"1345_CR61","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nature08636","volume":"463","author":"K Moro","year":"2010","unstructured":"Moro, K. et al. Innate production of TH2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cells. Nature 463, 540\u2013544 (2010).","journal-title":"Nature"},{"key":"1345_CR62","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nature13577","volume":"513","author":"C Schiering","year":"2014","unstructured":"Schiering, C. et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513, 564\u2013568 (2014). This study demonstrates that IL-33 is important for colonic Treg cell expansion and function, thus establishing its tissue-protective and regulatory roles.","journal-title":"Nature"},{"key":"1345_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161507","volume":"11","author":"J Siede","year":"2016","unstructured":"Siede, J. et al. IL-33 receptor-expressing regulatory T cells are highly activated, TH2 biased and suppress CD4 T cell proliferation through IL-10 and TGF\u03b2 release. PLoS ONE 11, e0161507 (2016).","journal-title":"PLoS ONE"},{"key":"1345_CR64","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.immuni.2015.06.006","volume":"42","author":"AB Molofsky","year":"2015","unstructured":"Molofsky, A. B., Savage, A. K. & Locksley, R. M. Interleukin-33 in tissue homeostasis, injury, and inflammation. Immunity 42, 1005\u20131019 (2015).","journal-title":"Immunity"},{"key":"1345_CR65","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.4049\/jimmunol.166.5.3143","volume":"166","author":"C Meisel","year":"2001","unstructured":"Meisel, C. et al. Regulation and function of T1\/ST2 expression on CD4+ T cells: induction of type 2 cytokine production by T1\/ST2 cross-linking. J. Immunol. 166, 3143\u20133150 (2001).","journal-title":"J. Immunol."},{"key":"1345_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15327","volume":"8","author":"SM Kallert","year":"2017","unstructured":"Kallert, S. M. et al. Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy. Nat. Commun. 8, 15327 (2017).","journal-title":"Nat. Commun."},{"key":"1345_CR67","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.immuni.2023.01.029","volume":"56","author":"AF Marx","year":"2023","unstructured":"Marx, A. F. et al. The alarmin interleukin-33 promotes the expansion and preserves the stemness of Tcf-1+ CD8+ T cells in chronic viral infection. Immunity 56, 813\u2013828 (2023). This study shows that IL-33 expands and preserves TCF1\u207a stem-like CD8\u207a T cells during chronic viral infection.","journal-title":"Immunity"},{"key":"1345_CR68","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.4049\/jimmunol.1500424","volume":"194","author":"T Nabekura","year":"2015","unstructured":"Nabekura, T., Girard, J. P. & Lanier, L. L. IL-33 receptor ST2 amplifies the expansion of NK cells and enhances host defense during mouse cytomegalovirus infection. J. Immunol. 194, 5948\u20135952 (2015).","journal-title":"J. Immunol."},{"key":"1345_CR69","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/ni.2045","volume":"12","author":"YJ Chang","year":"2011","unstructured":"Chang, Y. J. et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat. Immunol. 12, 631\u2013638 (2011).","journal-title":"Nat. Immunol."},{"key":"1345_CR70","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1038\/s41590-023-01655-2","volume":"24","author":"JW Griffith","year":"2023","unstructured":"Griffith, J. W. et al. Regulatory T cell-derived IL-1Ra suppresses the innate response to respiratory viral infection. Nat. Immunol. 24, 2091\u20132107 (2023).","journal-title":"Nat. Immunol."},{"key":"1345_CR71","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.cell.2015.08.021","volume":"162","author":"N Arpaia","year":"2015","unstructured":"Arpaia, N. et al. A distinct function of regulatory T cells in tissue protection. Cell 162, 1078\u20131089 (2015).","journal-title":"Cell"},{"key":"1345_CR72","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1164\/rccm.201406-1039OC","volume":"190","author":"DJ Jackson","year":"2014","unstructured":"Jackson, D. J. et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am. J. Respir. Crit. Care Med. 190, 1373\u20131382 (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1345_CR73","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4049\/jimmunol.1202806","volume":"191","author":"R Sesti-Costa","year":"2013","unstructured":"Sesti-Costa, R. et al. The IL-33\/ST2 pathway controls coxsackievirus B5-induced experimental pancreatitis. J. Immunol. 191, 283\u2013292 (2013).","journal-title":"J. Immunol."},{"key":"1345_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007974","volume":"13","author":"CC Hsieh","year":"2019","unstructured":"Hsieh, C. C. et al. Dynamic changes of soluble ST2 levels predicted fatality and were involved in coagulopathy in dengue fever in the elderly. PLoS Negl. Trop. Dis. 13, e0007974 (2019).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1345_CR75","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2217\/bmm-2020-0410","volume":"14","author":"Z Zeng","year":"2020","unstructured":"Zeng, Z. et al. Serum-soluble ST2 as a novel biomarker reflecting inflammatory status and illness severity in patients with COVID-19. Biomark. Med. 14, 1619\u20131629 (2020).","journal-title":"Biomark. Med."},{"key":"1345_CR76","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.3389\/fimmu.2018.02601","volume":"9","author":"C Afferni","year":"2018","unstructured":"Afferni, C. et al. The Pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity. Front. Immunol. 9, 2601 (2018).","journal-title":"Front. Immunol."},{"key":"1345_CR77","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/s41385-019-0176-y","volume":"12","author":"E Pastille","year":"2019","unstructured":"Pastille, E. et al. The IL-33\/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer. Mucosal Immunol. 12, 990\u20131003 (2019).","journal-title":"Mucosal Immunol."},{"key":"1345_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009236","volume":"12","author":"Y Nan","year":"2024","unstructured":"Nan, Y. et al. Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy. J. Immunother. Cancer 12, e009236 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1345_CR79","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.ccell.2025.02.017","volume":"43","author":"S Lamorte","year":"2025","unstructured":"Lamorte, S. et al. Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33. Cancer Cell 43, 955\u2013969 (2025).","journal-title":"Cancer Cell"},{"key":"1345_CR80","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41590-019-0555-2","volume":"21","author":"A Hatzioannou","year":"2020","unstructured":"Hatzioannou, A. et al. An intrinsic role of IL-33 in Treg cell-mediated tumor immunoevasion. Nat. Immunol. 21, 75\u201385 (2020).","journal-title":"Nat. Immunol."},{"key":"1345_CR81","doi-asserted-by":"publisher","first-page":"eaay1813","DOI":"10.1126\/science.aay1813","volume":"369","author":"S Taniguchi","year":"2020","unstructured":"Taniguchi, S. et al. Tumor-initiating cells establish an IL-33-TGF-\u03b2 niche signaling loop to promote cancer progression. Science 369, eaay1813 (2020).","journal-title":"Science"},{"key":"1345_CR82","doi-asserted-by":"publisher","first-page":"155961","DOI":"10.1016\/j.cyto.2022.155961","volume":"157","author":"WJ Yeoh","year":"2022","unstructured":"Yeoh, W. J., Vu, V. P. & Krebs, P. IL-33 biology in cancer: an update and future perspectives. Cytokine 157, 155961 (2022).","journal-title":"Cytokine"},{"key":"1345_CR83","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1016\/j.immuni.2024.07.004","volume":"57","author":"HL Erickson","year":"2024","unstructured":"Erickson, H. L. et al. Cancer stem cells release interleukin-33 within large oncosomes to promote immunosuppressive differentiation of macrophage precursors. Immunity 57, 1908\u20131922 (2024). This study reports that tumour-derived large oncosomes release IL-33 to drive immunosuppressive macrophage differentiation.","journal-title":"Immunity"},{"key":"1345_CR84","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/ijc.32779","volume":"146","author":"L Qi","year":"2020","unstructured":"Qi, L. et al. Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development. Int. J. Cancer 146, 1421\u20131434 (2020).","journal-title":"Int. J. Cancer"},{"key":"1345_CR85","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.4049\/jimmunol.1800627","volume":"201","author":"Z Jin","year":"2018","unstructured":"Jin, Z. et al. IL-33 released in the liver inhibits tumor growth via promotion of CD4+ and CD8+ T cell responses in hepatocellular carcinoma. J. Immunol. 201, 3770\u20133779 (2018).","journal-title":"J. Immunol."},{"key":"1345_CR86","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.bbrc.2019.08.058","volume":"518","author":"Y Xia","year":"2019","unstructured":"Xia, Y. et al. Endogenous IL-33 exerts CD8+ T cell antitumor responses overcoming pro-tumor effects by regulatory T cells in a colon carcinoma model. Biochem. Biophys. Res. Commun. 518, 331\u2013336 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1345_CR87","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/s12276-024-01249-4","volume":"56","author":"MH Kang","year":"2024","unstructured":"Kang, M. H. & Bae, Y. S. IL-33 and IL-33-derived DC-based tumor immunotherapy. Exp. Mol. Med. 56, 1340\u20131347 (2024).","journal-title":"Exp. Mol. Med."},{"key":"1345_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25057-w","volume":"12","author":"SS Ring","year":"2021","unstructured":"Ring, S. S. et al. Viral vector-mediated reprogramming of the fibroblastic tumor stroma sustains curative melanoma treatment. Nat. Commun. 12, 4734 (2021).","journal-title":"Nat. Commun."},{"key":"1345_CR89","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41586-024-08426-5","volume":"638","author":"M Amisaki","year":"2025","unstructured":"Amisaki, M. et al. IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer. Nature 638, 1076\u20131084 (2025). This study shows that IL-33 licenses ILC2s to form tertiary lymphoid structures in pancreatic cancer, which adds a new function to IL-33 signalling in cancer biology.","journal-title":"Nature"},{"key":"1345_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22764-2","volume":"12","author":"G Ercolano","year":"2021","unstructured":"Ercolano, G. et al. PPAR\u03b3 drives IL-33-dependent ILC2 pro-tumoral functions. Nat. Commun. 12, 2538 (2021).","journal-title":"Nat. Commun."},{"key":"1345_CR91","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1158\/2326-6066.CIR-21-0536","volume":"10","author":"RA Brog","year":"2022","unstructured":"Brog, R. A. et al. Superkine IL-2 and IL-33 armored CAR T cells reshape the tumor microenvironment and reduce growth of multiple solid tumors. Cancer Immunol. Res. 10, 962\u2013977 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"1345_CR92","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.1172\/JCI88625","volume":"126","author":"A Malik","year":"2016","unstructured":"Malik, A. et al. IL-33 regulates the IgA-microbiota axis to restrain IL-1\u03b1-dependent colitis and tumorigenesis. J. Clin. Invest. 126, 4469\u20134481 (2016).","journal-title":"J. Clin. Invest."},{"key":"1345_CR93","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser, R. & Blazar, B. R. Acute graft-versus-host disease \u2014 biologic process, prevention, and therapy. N. Engl. J. Med. 377, 2167\u20132179 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1345_CR94","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150927","volume":"132","author":"GK Dwyer","year":"2022","unstructured":"Dwyer, G. K. et al. IL-33 acts as a costimulatory signal to generate alloreactive TH1 cells in graft-versus-host disease. J. Clin. Invest. 132, e150927 (2022).","journal-title":"J. Clin. Invest."},{"key":"1345_CR95","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1182\/blood-2014-10-606830","volume":"125","author":"DK Reichenbach","year":"2015","unstructured":"Reichenbach, D. K. et al. The IL-33\/ST2 axis augments effector T-cell responses during acute GVHD. Blood 125, 3183\u20133192 (2015).","journal-title":"Blood"},{"key":"1345_CR96","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1182\/blood-2015-12-684142","volume":"128","author":"BM Matta","year":"2016","unstructured":"Matta, B. M. et al. Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. Blood 128, 427\u2013439 (2016).","journal-title":"Blood"},{"key":"1345_CR97","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122014","volume":"4","author":"J Yang","year":"2019","unstructured":"Yang, J. et al. Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease. JCI Insight 4, e122014 (2019).","journal-title":"JCI Insight"},{"key":"1345_CR98","doi-asserted-by":"publisher","first-page":"308ra160","DOI":"10.1126\/scitranslmed.aab0166","volume":"7","author":"J Zhang","year":"2015","unstructured":"Zhang, J. et al. ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Sci. Transl. Med. 7, 308ra160 (2015).","journal-title":"Sci. Transl. Med."},{"key":"1345_CR99","doi-asserted-by":"publisher","first-page":"104345","DOI":"10.1016\/j.cellimm.2021.104345","volume":"364","author":"R Venkatadri","year":"2021","unstructured":"Venkatadri, R. et al. Hybrid cytokine IL233 renders protection in murine acute graft vs host disease (aGVHD). Cell Immunol. 364, 104345 (2021).","journal-title":"Cell Immunol."},{"key":"1345_CR100","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMoa1213299","volume":"369","author":"MT Vander Lugt","year":"2013","unstructured":"Vander Lugt, M. T. et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N. Engl. J. Med. 369, 529\u2013539 (2013). This study establishes soluble ST2 as a biomarker for therapy-resistant GVHD and mortality after allogeneic stem cell transplantation.","journal-title":"N. Engl. J. Med."},{"key":"1345_CR101","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1182\/blood.2019000952","volume":"136","author":"GR Hill","year":"2020","unstructured":"Hill, G. R. & Koyama, M. Cytokines and costimulation in acute graft-versus-host disease. Blood 136, 418\u2013428 (2020).","journal-title":"Blood"},{"key":"1345_CR102","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser, R. & Blazar, B. R. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N. Engl. J. Med. 377, 2565\u20132579 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1345_CR103","first-page":"137","volume":"35","author":"J Chen","year":"2020","unstructured":"Chen, J., He, Y., Tu, L. & Duan, L. Dual immune functions of IL-33 in inflammatory bowel disease. Histol. Histopathol. 35, 137\u2013146 (2020).","journal-title":"Histol. Histopathol."},{"key":"1345_CR104","doi-asserted-by":"publisher","first-page":"27704","DOI":"10.18632\/oncotarget.15984","volume":"8","author":"L Tu","year":"2017","unstructured":"Tu, L. et al. IL-33-induced alternatively activated macrophage attenuates the development of TNBS-induced colitis. Oncotarget 8, 27704\u201327714 (2017).","journal-title":"Oncotarget"},{"key":"1345_CR105","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1136\/gutjnl-2011-301785","volume":"62","author":"MAK Sedhom","year":"2013","unstructured":"Sedhom, M. A. K. et al. Neutralisation of the interleukin-33\/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing In mice. Gut 62, 1714\u20131723 (2013).","journal-title":"Gut"},{"key":"1345_CR106","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41385-021-00386-7","volume":"14","author":"V Palmieri","year":"2021","unstructured":"Palmieri, V. et al. Interleukin-33 signaling exacerbates experimental infectious colitis by enhancing gut permeability and inhibiting protective TH17 immunity. Mucosal Immunol. 14, 923\u2013936 (2021).","journal-title":"Mucosal Immunol."},{"key":"1345_CR107","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ajpath.2015.11.028","volume":"186","author":"C De Salvo","year":"2016","unstructured":"De Salvo, C. et al. IL-33 drives eosinophil infiltration and pathogenic type 2 helper T-cell immune responses leading to chronic experimental ileitis. Am. J. Pathol. 186, 885\u2013898 (2016).","journal-title":"Am. J. Pathol."},{"key":"1345_CR108","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140624","volume":"131","author":"C De Salvo","year":"2021","unstructured":"De Salvo, C. et al. NOD2 drives early IL-33-dependent expansion of group 2 innate lymphoid cells during Crohn\u2019s disease-like ileitis. J. Clin. Invest. 131, e140624 (2021).","journal-title":"J. Clin. Invest."},{"key":"1345_CR109","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3389\/fimmu.2017.00475","volume":"8","author":"B Griesenauer","year":"2017","unstructured":"Griesenauer, B. & Paczesny, S. The ST2\/IL-33 axis in immune cells during inflammatory diseases. Front. Immunol. 8, 475 (2017).","journal-title":"Front. Immunol."},{"key":"1345_CR110","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3390\/ijms24010623","volume":"24","author":"I Aggeletopoulou","year":"2022","unstructured":"Aggeletopoulou, I., Tsounis, E. P. & Triantos, C. Molecular mechanisms underlying IL-33-mediated inflammation in inflammatory bowel disease. Int. J. Mol. Sci. 24, 623 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1345_CR111","first-page":"2429","volume":"21","author":"JC Masterson","year":"2015","unstructured":"Masterson, J. C. et al. Eosinophils and IL-33 perpetuate chronic inflammation and fibrosis in a pediatric population with stricturing Crohn\u2019s ileitis. Inflamm. Bowel Dis. 21, 2429\u20132440 (2015).","journal-title":"Inflamm. Bowel Dis."},{"key":"1345_CR112","doi-asserted-by":"publisher","first-page":"754413","DOI":"10.3389\/fimmu.2021.754413","volume":"12","author":"I Jacobs","year":"2021","unstructured":"Jacobs, I. et al. Role of eosinophils in intestinal inflammation and fibrosis in inflammatory bowel disease: an overlooked villain? Front. Immunol. 12, 754413 (2021).","journal-title":"Front. Immunol."},{"key":"1345_CR113","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/rheumatology\/kep402","volume":"49","author":"MY Mok","year":"2010","unstructured":"Mok, M. Y. et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology 49, 520\u2013527 (2010).","journal-title":"Rheumatology"},{"key":"1345_CR114","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1159\/000529931","volume":"15","author":"MY Mok","year":"2023","unstructured":"Mok, M. Y. et al. Interleukin-33 ameliorates murine systemic lupus erythematosus and is associated with induction of M2 macrophage polarisation and regulatory T cells. J. Innate Immun. 15, 485\u2013498 (2023).","journal-title":"J. Innate Immun."},{"key":"1345_CR115","doi-asserted-by":"publisher","first-page":"631603","DOI":"10.3389\/fimmu.2021.631603","volume":"12","author":"M Iwaszko","year":"2021","unstructured":"Iwaszko, M. et al. IL-33 gene polymorphisms as potential biomarkers of disease susceptibility and response to TNF inhibitors in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis patients. Front. Immunol. 12, 631603 (2021).","journal-title":"Front. Immunol."},{"key":"1345_CR116","doi-asserted-by":"publisher","first-page":"1012968","DOI":"10.3389\/fncel.2022.1012968","volume":"16","author":"T Xiong","year":"2022","unstructured":"Xiong, T., Wang, X., Zha, Y. & Wang, Y. Interleukin-33 regulates the functional state of microglia. Front. Cell Neurosci. 16, 1012968 (2022).","journal-title":"Front. Cell Neurosci."},{"key":"1345_CR117","doi-asserted-by":"publisher","first-page":"ENEURO.0147-17.","DOI":"10.1523\/ENEURO.0147-17.2017","volume":"4","author":"E Dohi","year":"2017","unstructured":"Dohi, E. et al. Behavioral changes in mice lacking Interleukin-33. eNeuro 4, ENEURO.0147-17.2017 (2017).","journal-title":"eNeuro"},{"key":"1345_CR118","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40478-016-0344-1","volume":"4","author":"D Allan","year":"2016","unstructured":"Allan, D. et al. Role of IL-33 and ST2 signalling pathway in multiple sclerosis: expression by oligodendrocytes and inhibition of myelination in central nervous system. Acta Neuropathol. Commun. 4, 75 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"1345_CR119","doi-asserted-by":"publisher","first-page":"40","DOI":"10.5001\/omj.2016.08","volume":"31","author":"A Jafarzadeh","year":"2016","unstructured":"Jafarzadeh, A. et al. Increased concentrations of Interleukin-33 in the serum and cerebrospinal fluid of patients with multiple sclerosis. Oman Med. J. 31, 40\u201345 (2016).","journal-title":"Oman Med. J."},{"key":"1345_CR120","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bbi.2014.08.002","volume":"44","author":"Y Pomeshchik","year":"2015","unstructured":"Pomeshchik, Y. et al. Interleukin-33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury. Brain Behav. Immun. 44, 68\u201381 (2015).","journal-title":"Brain Behav. Immun."},{"key":"1345_CR121","doi-asserted-by":"publisher","first-page":"E2705","DOI":"10.1073\/pnas.1604032113","volume":"113","author":"AK Fu","year":"2016","unstructured":"Fu, A. K. et al. IL-33 ameliorates Alzheimer\u2019s disease-like pathology and cognitive decline. Proc. Natl Acad. Sci. USA 113, E2705\u2013E2713 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1345_CR122","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.4049\/jimmunol.162.7.3882","volume":"162","author":"M L\u00f6hning","year":"1999","unstructured":"L\u00f6hning, M. et al. T1\/ST2 expression is enhanced on CD4+ T cells from schistosome egg-induced granulomas: analysis of Th cell cytokine coexpression ex vivo. J. Immunol. 162, 3882\u20133889 (1999).","journal-title":"J. Immunol."},{"key":"1345_CR123","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1084\/jem.191.6.1069","volume":"191","author":"MJ Townsend","year":"2000","unstructured":"Townsend, M. J., Fallon, P. G., Matthews, D. J., Jolin, H. E. & McKenzie, A. N. T1\/ST2-deficient mice demonstrate the importance of T1\/ST2 in developing primary T helper cell type 2 responses. J. Exp. Med. 191, 1069\u20131076 (2000).","journal-title":"J. Exp. Med."},{"key":"1345_CR124","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1084\/jem.190.7.895","volume":"190","author":"AJ Coyle","year":"1999","unstructured":"Coyle, A. J. et al. Crucial role of the interleukin 1 receptor family member T1\/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J. Exp. Med. 190, 895\u2013902 (1999).","journal-title":"J. Exp. Med."},{"key":"1345_CR125","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.4049\/jimmunol.1003020","volume":"186","author":"H Kouzaki","year":"2011","unstructured":"Kouzaki, H., Iijima, K., Kobayashi, T., O\u2019Grady, S. M. & Kita, H. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate TH2-type responses. J. Immunol. 186, 4375\u20134387 (2011).","journal-title":"J. Immunol."},{"key":"1345_CR126","doi-asserted-by":"publisher","first-page":"598","DOI":"10.4049\/jimmunol.1800292","volume":"202","author":"A Waddell","year":"2019","unstructured":"Waddell, A., Vallance, J. E., Hummel, A., Alenghat, T. & Rosen, M. J. IL-33 induces murine intestinal goblet cell differentiation indirectly via innate lymphoid cell IL-13 secretion. J. Immunol. 202, 598\u2013607 (2019).","journal-title":"J. Immunol."},{"key":"1345_CR127","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.immuni.2020.02.009","volume":"52","author":"AL Flamar","year":"2020","unstructured":"Flamar, A. L. et al. Interleukin-33 induces the enzyme tryptophan hydroxylase 1 to promote inflammatory group 2 innate lymphoid cell-mediated immunity. Immunity 52, 606\u2013619 (2020).","journal-title":"Immunity"},{"key":"1345_CR128","doi-asserted-by":"publisher","first-page":"1130933","DOI":"10.3389\/fimmu.2023.1130933","volume":"14","author":"PM Topczewska","year":"2023","unstructured":"Topczewska, P. M. et al. ILC2 require cell-intrinsic ST2 signals to promote type 2 immune responses. Front. Immunol. 14, 1130933 (2023).","journal-title":"Front. Immunol."},{"key":"1345_CR129","doi-asserted-by":"publisher","first-page":"677848","DOI":"10.3389\/fimmu.2021.677848","volume":"12","author":"S Van Nevel","year":"2021","unstructured":"Van Nevel, S. et al. Neutrophils affect IL-33 processing in response to the respiratory allergen alternaria alternata. Front. Immunol. 12, 677848 (2021).","journal-title":"Front. Immunol."},{"key":"1345_CR130","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.immuni.2023.01.005","volume":"56","author":"J Siewiera","year":"2023","unstructured":"Siewiera, J. et al. Circumvention of luteolysis reveals parturition pathways in mice dependent upon innate type 2 immunity. Immunity 56, 606\u2013619 (2023). This study reveals that IL-33-dependent ILC2 activation promotes uterine remodelling and parturition in mice.","journal-title":"Immunity"},{"key":"1345_CR131","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1038\/s41590-024-01982-y","volume":"25","author":"JM Inclan-Rico","year":"2024","unstructured":"Inclan-Rico, J. M. et al. MrgprA3 neurons drive cutaneous immunity against helminths through selective control of myeloid-derived IL-33. Nat. Immunol. 25, 2068\u20132084 (2024). This study describes a neuro-immune regulation axis where MrgprA3-expressing\u00a0sensory neurons control IL-33 release from myeloid cells in the skin and influence type 2 immune reactions.","journal-title":"Nat. Immunol."},{"key":"1345_CR132","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240103","volume":"221","author":"MJ Schuijs","year":"2024","unstructured":"Schuijs, M. J. et al. Interleukin-33-activated basophils promote asthma by regulating TH2 cell entry into lung tissue. J. Exp. Med. 221, e20240103 (2024).","journal-title":"J. Exp. Med."},{"key":"1345_CR133","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41590-018-0067-5","volume":"19","author":"C Cayrol","year":"2018","unstructured":"Cayrol, C. et al. Environmental allergens induce allergic inflammation through proteolytic maturation of IL-33. Nat. Immunol. 19, 375\u2013385 (2018).","journal-title":"Nat. Immunol."},{"key":"1345_CR134","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.jaci.2018.08.051","volume":"143","author":"L Ravanetti","year":"2019","unstructured":"Ravanetti, L. et al. IL-33 drives influenza-induced asthma exacerbations by halting innate and adaptive antiviral immunity. J. Allergy Clin. Immunol. 143, 1355\u20131370 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1345_CR135","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/ng.2830","volume":"46","author":"K Bonnelykke","year":"2014","unstructured":"Bonnelykke, K. et al. A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations. Nat. Genet. 46, 51\u201355 (2014).","journal-title":"Nat. Genet."},{"key":"1345_CR136","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41588-017-0014-7","volume":"50","author":"F Demenais","year":"2018","unstructured":"Demenais, F. et al. Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. Nat. Genet. 50, 42\u201353 (2018).","journal-title":"Nat. Genet."},{"key":"1345_CR137","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.jaci.2012.11.028","volume":"131","author":"NS Grotenboer","year":"2013","unstructured":"Grotenboer, N. S., Ketelaar, M. E., Koppelman, G. H. & Nawijn, M. C. Decoding asthma: translating genetic variation in IL33 and IL1RL1 into disease pathophysiology. J. Allergy Clin. Immunol. 131, 856\u2013865 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1345_CR138","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/ng.323","volume":"41","author":"DF Gudbjartsson","year":"2009","unstructured":"Gudbjartsson, D. F. et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat. Genet. 41, 342\u2013347 (2009).","journal-title":"Nat. Genet."},{"key":"1345_CR139","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa0906312","volume":"363","author":"MF Moffatt","year":"2010","unstructured":"Moffatt, M. F. et al. A large-scale, consortium-based genomewide association study of asthma. N. Engl. J. Med. 363, 1211\u20131221 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1345_CR140","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/ng.888","volume":"43","author":"DG Torgerson","year":"2011","unstructured":"Torgerson, D. G. et al. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat. Genet. 43, 887\u2013892 (2011).","journal-title":"Nat. Genet."},{"key":"1345_CR141","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006659","volume":"13","author":"D Smith","year":"2017","unstructured":"Smith, D. et al. A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma. PLoS Genet. 13, e1006659 (2017).","journal-title":"PLoS Genet."},{"key":"1345_CR142","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.immuni.2024.05.003","volume":"57","author":"K Alhallak","year":"2024","unstructured":"Alhallak, K. et al. Mast cells control lung type 2 inflammation via prostaglandin E2-driven soluble ST2. Immunity 57, 1274\u20131288 (2024).","journal-title":"Immunity"},{"key":"1345_CR143","doi-asserted-by":"publisher","first-page":"1533335","DOI":"10.3389\/fimmu.2025.1533335","volume":"16","author":"F Sheng","year":"2025","unstructured":"Sheng, F. et al. IL-33\/ST2 axis in diverse diseases: regulatory mechanisms and therapeutic potential. Front. Immunol. 16, 1533335 (2025).","journal-title":"Front. Immunol."},{"key":"1345_CR144","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","volume":"385","author":"ME Wechsler","year":"2021","unstructured":"Wechsler, M. E. et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N. Engl. J. Med. 385, 1656\u20131668 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1345_CR145","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","volume":"148","author":"SG Kelsen","year":"2021","unstructured":"Kelsen, S. G. et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial. J. Allergy Clin. Immunol. 148, 790\u2013798 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1345_CR146","doi-asserted-by":"publisher","first-page":"00183","DOI":"10.1183\/23120541.00183-2025","volume":"12","author":"J Corren","year":"2026","unstructured":"Corren, J. et al. FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma. ERJ Open Res. 12, 00183\u20132025 (2026).","journal-title":"ERJ Open Res."},{"key":"1345_CR147","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jacig.2022.07.002","volume":"1","author":"C Crim","year":"2022","unstructured":"Crim, C. et al. IL-33 receptor inhibition in subjects with uncontrolled asthma: a randomized, placebo-controlled trial. J. Allergy Clin. Immunol. Glob. 1, 198\u2013208 (2022).","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"1345_CR148","doi-asserted-by":"publisher","first-page":"01202","DOI":"10.1183\/23120541.01202-2025","volume":"12","author":"SN Georas","year":"2026","unstructured":"Georas, S. N. & Bourdin, A. IL-33 blockade in asthma: a story of hype, hope and hindsight. ERJ Open Res. 12, 01202\u20132025 (2026).","journal-title":"ERJ Open Res."},{"key":"1345_CR149","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3389\/fimmu.2019.00692","volume":"10","author":"A Gabryelska","year":"2019","unstructured":"Gabryelska, A., Kuna, P., Antczak, A., Bialasiewicz, P. & Panek, M. IL-33 mediated inflammation in chronic respiratory diseases-understanding the role of the member of IL-1 superfamily. Front. Immunol. 10, 692 (2019).","journal-title":"Front. Immunol."},{"key":"1345_CR150","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/thoraxjnl-2020-214712","volume":"76","author":"Q Huang","year":"2021","unstructured":"Huang, Q. et al. Role of the IL-33\/ST2 axis in cigarette smoke-induced airways remodelling in chronic obstructive pulmonary disease. Thorax 76, 750\u2013762 (2021).","journal-title":"Thorax"},{"key":"1345_CR151","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12890-021-01423-8","volume":"21","author":"H Joo","year":"2021","unstructured":"Joo, H., Park, S. J., Min, K. H. & Rhee, C. K. Association between plasma interleukin-33 level and acute exacerbation of chronic obstructive pulmonary disease. BMC Pulm. Med. 21, 86 (2021).","journal-title":"BMC Pulm. Med."},{"key":"1345_CR152","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1172\/JCI65570","volume":"123","author":"DE Byers","year":"2013","unstructured":"Byers, D. E. et al. Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J. Clin. Invest. 123, 3967\u20133982 (2013).","journal-title":"J. Clin. Invest."},{"key":"1345_CR153","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2015.02.011","volume":"42","author":"J Kearley","year":"2015","unstructured":"Kearley, J. et al. Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity 42, 566\u2013579 (2015).","journal-title":"Immunity"},{"key":"1345_CR154","doi-asserted-by":"publisher","first-page":"2402231","DOI":"10.1183\/13993003.02231-2024","volume":"66","author":"D Singh","year":"2025","unstructured":"Singh, D. et al. A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4. Eur. Respir. J. 66, 2402231 (2025).","journal-title":"Eur. Respir. J."},{"key":"1345_CR155","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1111\/bcp.16195","volume":"90","author":"MW Sadiq","year":"2024","unstructured":"Sadiq, M. W. et al. Population pharmacokinetic\/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease. Br. J. Clin. Pharmacol. 90, 3286\u20133295 (2024).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1345_CR156","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/cpt.3147","volume":"115","author":"F Reid","year":"2024","unstructured":"Reid, F. et al. A randomized phase I study of the anti-Interleukin-33 antibody tozorakimab in healthy adults and patients with chronic obstructive pulmonary disease. Clin. Pharmacol. Ther. 115, 565\u2013575 (2024).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1345_CR157","doi-asserted-by":"publisher","first-page":"00718","DOI":"10.1183\/23120541.00718-2023","volume":"10","author":"KF Rabe","year":"2024","unstructured":"Rabe, K. F. et al. AERIFY-1\/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD. ERJ Open Res. 10, 00718\u20132023 (2024).","journal-title":"ERJ Open Res."},{"key":"1345_CR158","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","volume":"10","author":"AJ Yousuf","year":"2022","unstructured":"Yousuf, A. J. et al. Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respir. Med. 10, 469\u2013477 (2022).","journal-title":"Lancet Respir. Med."},{"key":"1345_CR159","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","volume":"9","author":"KF Rabe","year":"2021","unstructured":"Rabe, K. F. et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir. Med. 9, 1288\u20131298 (2021).","journal-title":"Lancet Respir. Med."},{"key":"1345_CR160","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(26)00637-9","volume":"407","author":"A Papi","year":"2026","unstructured":"Papi, A. et al. Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials. Lancet 407, 2027\u20132039 (2026).","journal-title":"Lancet"},{"key":"1345_CR161","doi-asserted-by":"publisher","first-page":"220144","DOI":"10.1183\/16000617.0144-2022","volume":"32","author":"AA Calderon","year":"2023","unstructured":"Calderon, A. A. et al. Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD. Eur. Respir. Rev. 32, 220144 (2023).","journal-title":"Eur. Respir. Rev."},{"key":"1345_CR162","doi-asserted-by":"publisher","first-page":"8702","DOI":"10.3390\/ijms24108702","volume":"24","author":"L Riera-Martinez","year":"2023","unstructured":"Riera-Martinez, L., Canaves-Gomez, L., Iglesias, A., Martin-Medina, A. & Cosio, B. G. The role of IL-33\/ST2 in COPD and its future as an antibody therapy. Int. J. Mol. Sci. 24, 8702 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1345_CR163","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.cell.2016.06.040","volume":"166","author":"JI Odegaard","year":"2016","unstructured":"Odegaard, J. I. et al. Perinatal licensing of thermogenesis by IL-33 and ST2. Cell 166, 841\u2013854 (2016). This study establishes that perinatal IL-33\u2013ST2 signalling licenses adipose tissue thermogenic capacity.","journal-title":"Cell"},{"key":"1345_CR164","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1161\/CIRCRESAHA.110.218867","volume":"107","author":"AM Miller","year":"2010","unstructured":"Miller, A. M. et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ. Res. 107, 650\u2013658 (2010).","journal-title":"Circ. Res."},{"key":"1345_CR165","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1084\/jem.20121964","volume":"210","author":"AB Molofsky","year":"2013","unstructured":"Molofsky, A. B. et al. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J. Exp. Med. 210, 535\u2013549 (2013).","journal-title":"J. Exp. Med."},{"key":"1345_CR166","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nature14115","volume":"519","author":"JR Brestoff","year":"2015","unstructured":"Brestoff, J. R. et al. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature 519, 242\u2013246 (2015). This study reveals that IL-33-activated ILC2s induce adipose tissue \u2018beiging\u2019 via methionine-enkephalin peptides, increasing UCP1 expression and energy expenditure of adipocytes.","journal-title":"Nature"},{"key":"1345_CR167","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/eji.201444969","volume":"45","author":"M Hashiguchi","year":"2015","unstructured":"Hashiguchi, M. et al. IL-33 activates eosinophils of visceral adipose tissue both directly and via innate lymphoid cells. Eur. J. Immunol. 45, 876\u2013885 (2015).","journal-title":"Eur. J. Immunol."},{"key":"1345_CR168","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.4049\/jimmunol.1500020","volume":"194","author":"JM Han","year":"2015","unstructured":"Han, J. M. et al. IL-33 reverses an obesity-induced deficit in visceral adipose tissue ST2+ T regulatory cells and ameliorates adipose tissue inflammation and insulin resistance. J. Immunol. 194, 4777\u20134783 (2015).","journal-title":"J. Immunol."},{"key":"1345_CR169","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.immuni.2019.12.002","volume":"52","author":"M Delacher","year":"2020","unstructured":"Delacher, M. et al. Precursors for nonlymphoid-tissue Treg cells reside in secondary lymphoid organs and are programmed by the transcription factor BATF. Immunity 52, 295\u2013312 (2020).","journal-title":"Immunity"},{"key":"1345_CR170","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/ijo.2012.118","volume":"37","author":"M Zeyda","year":"2013","unstructured":"Zeyda, M. et al. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int. J. Obes. 37, 658\u2013665 (2013).","journal-title":"Int. J. Obes."},{"key":"1345_CR171","doi-asserted-by":"publisher","first-page":"1335651","DOI":"10.3389\/fimmu.2024.1335651","volume":"15","author":"S Soedono","year":"2024","unstructured":"Soedono, S. et al. Obese visceral adipose dendritic cells downregulate regulatory T cell development through IL-33. Front. Immunol. 15, 1335651 (2024).","journal-title":"Front. Immunol."},{"key":"1345_CR172","doi-asserted-by":"publisher","first-page":"eadl4909","DOI":"10.1126\/sciimmunol.adl4909","volume":"10","author":"C Elkins","year":"2025","unstructured":"Elkins, C. et al. Obesity reshapes regulatory T cells in the visceral adipose tissue by disrupting cellular cholesterol homeostasis. Sci. Immunol. 10, eadl4909 (2025).","journal-title":"Sci. Immunol."},{"key":"1345_CR173","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41590-024-01753-9","volume":"25","author":"SV Torres","year":"2024","unstructured":"Torres, S. V. et al. Two regulatory T cell populations in the visceral adipose tissue shape systemic metabolism. Nat. Immunol. 25, 496\u2013511 (2024). This study identifies two distinct Treg\u00a0cell subsets in visceral adipose tissue: IL-33-driven ST2\u207a Treg cells that support glucose homeostasis, and CXCR3\u207a Treg\u00a0cells that act in an immune-modulating manner and restrain inflammation.","journal-title":"Nat. Immunol."},{"key":"1345_CR174","doi-asserted-by":"publisher","first-page":"eabc9934","DOI":"10.1126\/sciimmunol.abc9934","volume":"7","author":"X Wu","year":"2022","unstructured":"Wu, X. et al. BATF promotes group 2 innate lymphoid cell-mediated lung tissue protection during acute respiratory virus infection. Sci. Immunol. 7, eabc9934 (2022).","journal-title":"Sci. Immunol."},{"key":"1345_CR175","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.immuni.2015.01.020","volume":"42","author":"DMW Zaiss","year":"2015","unstructured":"Zaiss, D. M. W., Gause, W. C., Osborne, L. C. & Artis, D. Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity 42, 216\u2013226 (2015).","journal-title":"Immunity"},{"key":"1345_CR176","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.immuni.2021.09.010","volume":"54","author":"M Faas","year":"2021","unstructured":"Faas, M. et al. IL-33-induced metabolic reprogramming controls the differentiation of alternatively activated macrophages and the resolution of inflammation. Immunity 54, 2531\u20132546 (2021).","journal-title":"Immunity"},{"key":"1345_CR177","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/ni.2131","volume":"12","author":"LA Monticelli","year":"2011","unstructured":"Monticelli, L. A. et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat. Immunol. 12, 1045\u20131054 (2011).","journal-title":"Nat. Immunol."},{"key":"1345_CR178","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/JID.2015.406","volume":"136","author":"GD Rak","year":"2016","unstructured":"Rak, G. D. et al. IL-33-dependent group 2 innate lymphoid cells promote cutaneous wound healing. J. Invest. Dermatol. 136, 487\u2013496 (2016).","journal-title":"J. Invest. Dermatol."},{"key":"1345_CR179","doi-asserted-by":"publisher","first-page":"1351405","DOI":"10.3389\/fimmu.2024.1351405","volume":"15","author":"S Wachtendorf","year":"2024","unstructured":"Wachtendorf, S. et al. The ST2+ Treg\/amphiregulin axis protects from immune-mediated hepatitis. Front. Immunol. 15, 1351405 (2024).","journal-title":"Front. Immunol."},{"key":"1345_CR180","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3390\/ijms21041544","volume":"21","author":"WY Chen","year":"2020","unstructured":"Chen, W. Y., Li, L. C., Wu, Y. H., Yang, J. L. & Tzeng, H. T. Emerging roles of interleukin-33-responsive kidney group 2 innate lymphoid cells in acute kidney injury. Int. J. Mol. Sci. 21, 1544 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1345_CR181","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41423-024-01178-2","volume":"21","author":"S Ryu","year":"2024","unstructured":"Ryu, S. et al. The protective roles of integrin \u03b14\u03b27 and amphiregulin-expressing innate lymphoid cells in lupus nephritis. Cell Mol. Immunol. 21, 723\u2013737 (2024).","journal-title":"Cell Mol. Immunol."},{"key":"1345_CR182","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.7150\/thno.51648","volume":"11","author":"WY Chen","year":"2021","unstructured":"Chen, W. Y. et al. Group 2 innate lymphoid cells contribute to IL-33-mediated alleviation of cardiac fibrosis. Theranostics 11, 2594\u20132611 (2021).","journal-title":"Theranostics"},{"key":"1345_CR183","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01345-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01345-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01345-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:04:55Z","timestamp":1788793495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01345-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":183,"alternative-id":["1345"],"URL":"https:\/\/doi.org\/10.1038\/s41577-026-01345-8","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"15 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}